Y-mAbs Therapeutics (NASDAQ:YMAB) Given New $20.00 Price Target at Oppenheimer
Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) had its price objective trimmed by Oppenheimer from $21.00 to $20.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock. YMAB has been the subject of a number of other reports. Bank of America downgraded Y-mAbs Therapeutics from […]
Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) had its price objective trimmed by Oppenheimer from $21.00 to $20.00 in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock. YMAB has been the subject of a number of other reports. Bank of America downgraded Y-mAbs Therapeutics from […]
